<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

CP 945598 hydrochloride - Otenabant hydrochloride

產(chǎn)品貨號(hào)

Axon 2119 CAS [686347-12-6] MF C25H25Cl2N7O.HClMW 546.88 Purity: 99% Soluble in DMSO Description Hydrochloride formulation of the potent and selective cannabinoid CB1 receptor antagonist CP-945,598 (Otenabant HCl; Ki values 0.7 nM and 0.2 nM in binding and functional assays, respectively) for the management of obesity. CP945598 HCl exhibits a >10000 fold selectivity over CB2, and lacks significant, or meaningful, activity at a large panel of receptors, enzymes, and ion channels. Parent molecule available as well (Axon 2015) References Certificates Categories Extra info J.R. Hadcock et al. In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity. Biochem Biophys Res Commun. 2010 Apr 2;394(2):366-71. ? L.J. Aronne et al. Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance. Obesity (Silver Spring). 2011 Jul;19(7):1404-14. Certificate of Analysis Material Safety Data Sheet Cardiovascular CNS Diabetes & Metabolism Pain & Inflammation CB1 A13 Pfizer Licensed Products CB1 antagonist Chemical name 1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)-4-(ethylamino)piperidine-4-carboxamide hydrochloride Source information Pfizer compound; Sold for research purposes under agreement from Pfizer Inc. Parent CAS No. [686344-29-6] Order Size Unit Price Stock 10 mg €135.00 In Stock

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

CP 945598 hydrochloride - Otenabant hydrochloride

Based on 12 reference(s) in Google Scholar 9 10 12

Axon 2119

CAS [686347-12-6]

MF C25H25Cl2N7O.HCl
MW 546.88

Purity: 99%
Soluble in DMSO

CP 945598 hydrochloride

Description

Hydrochloride formulation of the potent and selective cannabinoid CB1 receptor antagonist CP-945,598 (Otenabant HCl; Ki values 0.7 nM and 0.2 nM in binding and functional assays, respectively) for the management of obesity. CP945598 HCl exhibits a >10000 fold selectivity over CB2, and lacks significant, or meaningful, activity at a large panel of receptors, enzymes, and ion channels. Parent molecule available as well (Axon 2015)

J.R. Hadcock et al. In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity. Biochem Biophys Res Commun. 2010 Apr 2;394(2):366-71.

L.J. Aronne et al. Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance. Obesity (Silver Spring). 2011 Jul;19(7):1404-14.

Certificate of Analysis
Material Safety Data Sheet

Cardiovascular CNS Diabetes & Metabolism Pain & Inflammation CB1 A13 Pfizer Licensed Products

CB1 antagonist

Chemical name

1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)-4-(ethylamino)piperidine-4-carboxamide hydrochloride

Source information

Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Parent CAS No.

[686344-29-6]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>